3.4. Inhibition of HO-1 Enzymatic Activity Improved the Pharmacological Response of Myeloma PCs to BTZ by Increasing ER Stress and Mitochondrial Damage. The gene discussed is HMOX1; the disease is plasma cell myeloma.